The Unitaid-funded ASCENT project aims to help patients succeed in TB treatment using digital adherence technology.

Tuberculosis (TB) is still the deadliest infectious disease worldwide, killing over 4.000 people every day. This is unnecessary as TB can be cured with appropriate treatment. A number of barriers however, prevent patients from recovering from this disease, including long and complicated treatment regimens that involve the daily intake of medicines over the course of 6-24 months.

Missing even a few daily doses or interrupting treatment can lead to resistance to the TB medicines and/or return of the disease later in life. Therefore, patients normally need to be observed when taking their daily medication either by visiting the health center or by a health care worker at their home.

Obviously, these supportive measures put a burden on both the patient and the health system. By leveraging today’s smart information and (mobile) communication technologies the ASCENT project (Adherence Support Coalition to End TB) aims to support TB patients with their treatment in a modern and more effective way.

By generating evidence, establishing a global market and engaging stakeholders, ASCENT aims to make future scale up possible so that these digital innovations can be available to all TB patients worldwide.

news & Stories

Why adherence to treatment is so important

Problem statement:

Missing doses of medication during tuberculosis treatment has serious negative effects
Patients are more likely to stop their TB treatment
Patients can develop resistance to anti TB drugs
Patients are more likely to get TB again

what is Tuberculosis?

Consortium partners

Consortium partners

more about the ascent project